Sam Brusco, Associate Editor01.04.24
SimBioSys has received its first U.S. Food and Drug Administration (FDA) 510(k) clearance for its first software application on its cloud-based digital medicine platform, TumorSight.
TumorSight Viz uses standard-of-care medical imaging (DCE MRI) to create 3D spatial visualization and key insights to give a more comprehensive understanding of the specific cancer and the options available to treat it.
The tech uses artificial intelligence (AI) to automatically segment the tumor and surrounding tissue to display the 3D visualization. TumorSight also provides tumor volume, tumor-to-breast volume, and tumor distance to key anatomical structures in the breast.
“This is a landmark moment for the SimBioSys team and our many collaborators. It is our springboard to begin fulfilling our mission to redefine precision medicine as we launch this first application and target further expansion in clinical utilities within breast cancer as well as across other solid tumors,” said Tushar Pandey, co-founder and CEO of SimBioSys.
Earlier this week, SimBioSys announced a strategic collaboration with Mayo Clinic to develop digital precision medicine solutions for breast cancer patients.
“With the significant increase in use of MRIs in early-stage breast cancer, we have a real opportunity to bring imaging to the forefront of precision medicine. Our first TumorSight application offers automated valuable insights to the cancer care team,” added Pandey. “Equipped with this information, clinicians can provide treatment that is truly personalized to each patient, and patients will feel more empowered in this important decision-making process.”
TumorSight Viz uses standard-of-care medical imaging (DCE MRI) to create 3D spatial visualization and key insights to give a more comprehensive understanding of the specific cancer and the options available to treat it.
The tech uses artificial intelligence (AI) to automatically segment the tumor and surrounding tissue to display the 3D visualization. TumorSight also provides tumor volume, tumor-to-breast volume, and tumor distance to key anatomical structures in the breast.
“This is a landmark moment for the SimBioSys team and our many collaborators. It is our springboard to begin fulfilling our mission to redefine precision medicine as we launch this first application and target further expansion in clinical utilities within breast cancer as well as across other solid tumors,” said Tushar Pandey, co-founder and CEO of SimBioSys.
Earlier this week, SimBioSys announced a strategic collaboration with Mayo Clinic to develop digital precision medicine solutions for breast cancer patients.
“With the significant increase in use of MRIs in early-stage breast cancer, we have a real opportunity to bring imaging to the forefront of precision medicine. Our first TumorSight application offers automated valuable insights to the cancer care team,” added Pandey. “Equipped with this information, clinicians can provide treatment that is truly personalized to each patient, and patients will feel more empowered in this important decision-making process.”